Evidence map›Paper›PMID 29525328›Full record

ArticleJACC. Heart failure2018

Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure: Insights From ASCEND-HF Trial.

Lukasz P Cerbin, Andrew P Ambrosy, Stephen J Greene, Paul W Armstrong, Javed Butler, Adrian Coles, Adam D DeVore, Justin A Ezekowitz, Adrian F Hernandez, Marco Metra and 7 more

Abstract read
In one paragraph

Article in JACC. Heart failure, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Lukasz P CerbinDepartment of Internal Medicine, Duke University Medical Center, Durham, North Carolina. Electronic address: lukasz.p.cerbin@duke.edu.
Andrew P AmbrosyDepartment of Internal Medicine, Duke University Medical Center, Durham, North Carolina; Duke Clinical Research Institute, North Carolina, Durham, North Carolina.
Stephen J GreeneDepartment of Internal Medicine, Duke University Medical Center, Durham, North Carolina; Duke Clinical Research Institute, North Carolina, Durham, North Carolina.
Paul W ArmstrongCanadian VIGOUR Centre, University of Alberta, Edmonton, Alberta, Canada.
Javed ButlerDivision of Cardiology, Stony Brook University, Stony Brook, New York.
Adrian ColesDuke Clinical Research Institute, North Carolina, Durham, North Carolina.
Adam D DeVoreDepartment of Internal Medicine, Duke University Medical Center, Durham, North Carolina; Duke Clinical Research Institute, North Carolina, Durham, North Carolina.
Justin A EzekowitzCanadian VIGOUR Centre, University of Alberta, Edmonton, Alberta, Canada.
Adrian F HernandezDepartment of Internal Medicine, Duke University Medical Center, Durham, North Carolina; Duke Clinical Research Institute, North Carolina, Durham, North Carolina.
Marco MetraCardiology, University of Brescia, Brescia, Italy.
Randall C StarlingHeart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, Ohio.
Wilson TangHeart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, Ohio.
John R TeerlinkSection of Cardiology, San Francisco Veteran Affairs Medical Center, and School of Medicine, University of California-San Francisco, San Francisco, California.
Adriaan A VoorsUniversity of Groningen, Groningen, the Netherlands.
Angie WuDuke Clinical Research Institute, North Carolina, Durham, North Carolina.
Christopher M O'ConnorInova Heart and Vascular Institute, Falls Church, Virginia.
Robert J MentzDepartment of Internal Medicine, Duke University Medical Center, Durham, North Carolina; Duke Clinical Research Institute, North Carolina, Durham, North Carolina.

Funding

Postdoctoral Training in Cardiovascular Clinical ResearchT32HL069749 · NHLBI · DUKE UNIVERSITY · PI MARK, DANIEL B · 2003 to 2023
$6.7M
NHLBI NIH HHS T32 HL069749
6 · The paper itself

Abstract

objectivesAs the largest acute heart failure (AHF) trial conducted to date, the global ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) trial database presented an opportunity to systematically describe the relationship among time of hospital presentation, clinical profile, inpatient management, and outcomes among patients admitted with AHF.

backgroundTime of hospital presentation has been shown to impact outcomes among patients hospitalized with many conditions. However, the association among time of presentation and patient characteristics, management, and clinical outcomes among patients hospitalized with AHF has not been well characterized.

methodsA post hoc analysis of the ASCEND-HF trial was performed, which enrolled 7,141 patients hospitalized for AHF. Patients were divided based on when they presented to the hospital; regular hours were defined as 9 am to 5 pm, Monday through Friday, and off hours were defined as 5 pm to 9 am, Monday through Friday and weekends. Clinical characteristics and outcomes were compared by time of presentation.

resultsOverall, 3,298 patients (46%) presented during off hours. Off-hour patients were more likely to have orthopnea (80% vs. 74%, respectively) and rales (56% vs. 49%, respectively) than regular-hour patients. Off-hour patients were more likely to receive intravenous (IV) nitroglycerin (18% vs. 11%, respectively) and IV loop diuretics (92% vs. 86%, respectively) as initial therapy and reported greater relief from dyspnea at 24 h (odds ratio [OR]: 1.14; 95% confidence interval [CI]: 1.04 to 1.24; p = 0.01) than regular-hour patients. After adjustment, off-hour presentation was associated with significantly lower 30-day mortality (OR: 0.74; 95% CI: 0.57 to 0.96; p = 0.03) and 180-day mortality (hazard ratio [HR]: 0.82; 95% CI: 0.72 to 0.94; p = 0.01) but similar 30-day rehospitalization rates (p = 0.40).

conclusionsIn this AHF trial, patients admitted during off hours exhibited a distinct clinical profile, experienced greater dyspnea relief, and had lower post-discharge mortality than regular-hour patients. These findings have implications for future AHF trials.

Indexed as

After-Hours CareMortalityAcute DiseaseAgedDyspneaEmergency Service, HospitalFemaleHeart FailureHumansMaleMiddle AgedNitroglycerinPatient ReadmissionPosturePrognosisProportional Hazards ModelsNitroglycerinSodium Potassium Chloride Symporter InhibitorsVasodilator AgentsASCEND-HFheart failurepresentation

Identifiers

PMID29525328
PMCPMC7445462

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.